tetano
Editor, Senior Moderator
Sci Immunol
. 2026 Aug 28;11(122):eaec9853.
doi: 10.1126/sciimmunol.aec9853. Epub 2026 Aug 28.
Davide Marotta 1 2 , Chiara Perucchini 1 2 , Marta Grillo 1 2 , Valeria Fumagalli 1 2 , Pietro Di Lucia 1 2 , Jordan Rixon 1 , Micol Ravà 1 , Leonardo Giustini 1 , Chiara Malpighi 1 , Giulia D'Uonnolo 1 , Mariangela Scavone 3 , Violette Mouro 1 2 , Caitlin Abbott 1 , Natalia Stachura-Chyla 4 , Francesco Andreata 1 2 , Erica Scalambrino 5 , Marigrazia Clerici 5 , Lorena Donnici 6 , Marika Longo Minnolo 6 7 , Donato Inverso 1 2 , Raffaele De Francesco 6 7 , Mauro Gaya 8 , Zaverio M Ruggeri 9 10 , Armando Tripodi 5 , Gian Marco Podda 5 , Luca G Guidotti 1 2 , Matteo Iannacone 1 2 , Marco De Giovanni 1 2
Affiliations
Elderly individuals affected by COVID-19 are vulnerable to severe respiratory failure for reasons that have remained poorly defined. Here, we show that platelet-released serotonin drives lung pathology in a mouse model of age-associated disease severity after SARS-CoV-2 infection. In middle-aged mice and aged human healthy donors, platelet serotonin release upon activation was enhanced, and increased morbidity with respiratory dysfunction was associated with activated platelets aggregating and promoting fibrin deposition in the lung microvasculature. Pharmacologic or genetic disruption of serotonin uptake, or blockade of serotonin-dependent signaling, attenuated platelet activation and protected against respiratory distress, independently of viral replication and immune responses. Inhibition of fibrin formation similarly reduced disease severity, implicating serotonin-driven platelet procoagulant activity as a key contributor to age-related lung dysfunction. Thus, serotonin-mediated platelet procoagulant activity is a major contributor to respiratory insufficiency during SARS-CoV-2 infection and a potential therapeutic target for preserving pulmonary function, particularly in the elderly.
. 2026 Aug 28;11(122):eaec9853.
doi: 10.1126/sciimmunol.aec9853. Epub 2026 Aug 28.
Platelet-derived serotonin drives age-related lung pathology in SARS-CoV-2 infection
Davide Marotta 1 2 , Chiara Perucchini 1 2 , Marta Grillo 1 2 , Valeria Fumagalli 1 2 , Pietro Di Lucia 1 2 , Jordan Rixon 1 , Micol Ravà 1 , Leonardo Giustini 1 , Chiara Malpighi 1 , Giulia D'Uonnolo 1 , Mariangela Scavone 3 , Violette Mouro 1 2 , Caitlin Abbott 1 , Natalia Stachura-Chyla 4 , Francesco Andreata 1 2 , Erica Scalambrino 5 , Marigrazia Clerici 5 , Lorena Donnici 6 , Marika Longo Minnolo 6 7 , Donato Inverso 1 2 , Raffaele De Francesco 6 7 , Mauro Gaya 8 , Zaverio M Ruggeri 9 10 , Armando Tripodi 5 , Gian Marco Podda 5 , Luca G Guidotti 1 2 , Matteo Iannacone 1 2 , Marco De Giovanni 1 2
Affiliations
- PMID: 42664308
- DOI: 10.1126/sciimmunol.aec9853
Abstract
Elderly individuals affected by COVID-19 are vulnerable to severe respiratory failure for reasons that have remained poorly defined. Here, we show that platelet-released serotonin drives lung pathology in a mouse model of age-associated disease severity after SARS-CoV-2 infection. In middle-aged mice and aged human healthy donors, platelet serotonin release upon activation was enhanced, and increased morbidity with respiratory dysfunction was associated with activated platelets aggregating and promoting fibrin deposition in the lung microvasculature. Pharmacologic or genetic disruption of serotonin uptake, or blockade of serotonin-dependent signaling, attenuated platelet activation and protected against respiratory distress, independently of viral replication and immune responses. Inhibition of fibrin formation similarly reduced disease severity, implicating serotonin-driven platelet procoagulant activity as a key contributor to age-related lung dysfunction. Thus, serotonin-mediated platelet procoagulant activity is a major contributor to respiratory insufficiency during SARS-CoV-2 infection and a potential therapeutic target for preserving pulmonary function, particularly in the elderly.